Related Experiment Video
Updated: Jul 19, 2026
A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
Somatostatin receptor imaging for neuroendocrine tumors
Wouter W de Herder1, Dik J Kwekkeboom, Richard A Feelders
1Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The Netherlands. w.w.deherder@erasmusmc.nl
Abstract:
Tumors and metastases that express the somatostatin receptor subtypes sst2 sst3 or sst5 can be visualized in vivo after injection of radiolabeled octapeptide somatostatin analogs, like (111)In-pentetreotide. (111)In-pentetreotide scintigraphy also allows for more accurate staging of the disease by demonstrating tumor sites, which were not shown by conventional imaging. (111)In-pentetreotide scintigraphy may also detect resectable tumors that would have remained unrecognized using conventional radiological imaging techniques; it may prevent surgery with curative intent in those patients whose tumors have metastasized to a greater extend than could be detected with conventional radiological imaging and it may be used to select patients for treatment with the currently available octapeptide somatostatin analogs or with tumor targeted radioactive treatment with radiolabelled somatostatin analogs. (111)In-pentetreotide scintigraphy has also been used to select patients with pituitary tumors for medical treatment with octapeptide analogs, but its clinical usefulness for this purpose seems to be limited. It further allows scar tissue to be differentiated from tumor recurrence after the pituitary surgery or radiotherapy. However, a large variety of lesions in and around the pituitary region also express somatostatin receptors and, therefore, can be visualized by (111)In-pentetreotide scintigraphy.
Insights
Radiolabeled somatostatin analogs like (111)In-pentetreotide visualize tumors expressing somatostatin receptors. This imaging aids in accurate disease staging, detection of resectable tumors, and patient selection for targeted therapies.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- Somatostatin receptor subtypes (sst2, sst3, sst5) are expressed in various tumors and metastases.
- Radiolabeled somatostatin analogs enable in vivo visualization of these receptor-positive malignancies.
Purpose of the Study:
- To evaluate the utility of (111)In-pentetreotide scintigraphy for tumor visualization, staging, and treatment selection.
- To assess its role in managing pituitary tumors and differentiating scar tissue from recurrence.
Main Methods:
- Administration of radiolabeled octapeptide somatostatin analogs, specifically (111)In-pentetreotide.
- In vivo scintigraphy for imaging somatostatin receptor-positive lesions.
- Comparison with conventional radiological imaging techniques.
Main Results:
- (111)In-pentetreotide scintigraphy accurately stages disease by revealing occult tumor sites.
- It identifies resectable tumors missed by conventional imaging and prevents unnecessary surgery in advanced metastatic cases.
- The technique aids in selecting patients for somatostatin analog therapy or radiolabeled somatostatin analog treatment.
- Its use in pituitary tumor selection for medical treatment is limited, but it differentiates scar tissue from recurrence.
Conclusions:
- (111)In-pentetreotide scintigraphy is a valuable tool for visualizing somatostatin receptor-positive tumors and metastases.
- It improves disease staging, detects previously unrecognized tumors, and guides therapeutic decisions.
- While useful for pituitary lesions, its clinical utility requires further investigation.
Related Concept Videos
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...